Johnson & Johnson (JNJ)
Johnson & Johnson (JNJ) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)
Johnson & Johnson (NYSE:JNJ ) Morgan Stanley 22nd Annual Global Healthcare Conference September 4, 2024 10:45 AM ET Company Participants Joaquin Duato - CEO & Chairman John Reed - Head of Pharma R&D Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn Great. All right.
3 Dividend Stocks to Double Up on Right Now
Verizon offers a high-yielding and steadily rising dividend. Johnson & Johnson pays a very healthy dividend.
Johnson & Johnson (JNJ) Increases Despite Market Slip: Here's What You Need to Know
Johnson & Johnson (JNJ) concluded the recent trading session at $167.16, signifying a +0.78% move from its prior day's close.
Is Johnson & Johnson the Best Dividend Stock for You?
Johnson & Johnson is a remarkably consistent business. A fortress-like balance sheet all but guarantees the dividend's safety.
JNJ Seeks First FDA Nod for Autoimmune Disease Drug Nipocalimab
The Johnson & Johnson filing seeks the FDA's approval for nipocalimab to treat generalized myasthenia gravis in a broad population of antibody-positive patients.
Must-have stocks for passive income in 2025
In addition to profiting from ordinary trading activities, the stock market offers opportunities for investors seeking passive income through dividend payouts.
Drop Johnson & Johnson, Pick These Steady Eddie Stocks?
If you are a Johnson & Johnson investor and have been enjoying the stock's steady dividends, it may be time to look elsewhere. As of this moment, we find DaVita - a healthcare company focused on kidney dialysis services - and Duke Energy - an electric and natural gas utility company based in North Carolina - as more attractive buys than Johnson & Johnson.
Johnson & Johnson's Golden Cross: A Bullish Prescription For Investors?
Johnson & Johnson JNJ has just made a significant technical move, achieving a Golden Cross.
J&J's Stock Up 12.8% in 3 Months: Time to Buy, Sell or Hold?
We suggest a new investor should avoid buying J&J's stock now due to uncertainty surrounding its legal battles.
J&J's Rybrevant Receives EU Approval for Expanded Use in NSCLC
The European Commission approves JNJ's Rybrevant in combination with chemotherapy for treating EGFR-mutated NSCLC following failure of prior therapy.
Johnson & Johnson (JNJ) Stock Dips While Market Gains: Key Facts
Johnson & Johnson (JNJ) closed the most recent trading day at $162.95, moving -1.01% from the previous trading session.
JNJ Stock A Winner Right Now?
We believe that Johnson & Johnson stock (NYSE: JNJ) is currently a better pick than Procter & Gamble stock (NYSE: PG) as it appears to show more promise over the coming years. The decision to invest often comes down to finding the best stocks within the scope of certain characteristics that suit an investment style.
